Investigating novel therapies for brain tumors - the roles of MCT4, cellular senescence, and arsenic trioxide treatment

Brain tumors;pilocytic astrocytoma;glioblastoma;not listed

Lim, Kah SuanSemenza, Gregg L. ;

Johns Hopkins University

关键词: Brain tumors;    pilocytic astrocytoma;    glioblastoma;    not listed;   

Others  :  https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/36976/LIM-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

瑞士|英语

来源: JOHNS HOPKINS DSpace Repository

【 摘 要 】

My studies focused on characterizing signaling and metabolic pathways involved in the pathobiology of brain tumors in order to develop improved therapies. One project was centered on investigating oncogenic KIAA1549-BRAF fusion induced senescence as a growth suppressive mechanism in pilocytic astrocytoma. We found that loss of expression of tumor suppressor p16 lead to significantly decreased survival in pilocytic astrocytoma patients. Another major focus was on metabolic targeting in glioblastoma cells. We found that the lactate exporter MCT4 was specifically upregulated under hypoxic conditions in glioblastoma cells, and its overexpression was significantly linked to survival. Silencing MCT4 in glioblastoma neurospheres led to decreased growth in vitro and in vivo, inhibition of clonogenic capacity, and reductions in CD133-positive stem-like tumor cells. This was partially due to an induction of apoptosis. Interestingly, we found that this apoptotic induction and growth inhibition was not due to lack of lactate export, but instead, due to an inhibition of the HIF response, highlighting the importance of aberrant metabolic regulation in cancer. Finally, we investigated the possibility of targeting Notch and Hedgehog signaling simultaneously in glioblastoma neurospheres using arsenic trioxide. We found that aberrant Notch and Hedgehog pathway signaling was decreased following arsenic trioxide treatment, and this decrease was accompanied by decreased neurosphere growth and proliferation, decreased clonogenic capacity, decreased CD133-positive cells, and increased apoptosis. These studies thus identify mechanisms by which several hallmarks of cancer are altered in brain tumors, andour preclinical data suggest some potential therapeutic applications. However, it is important to note that targeting only one or two hallmark changes in cancer often leads to therapeutic resistance, and multimodal therapies will likely be necessary if we are to cure aggressive brain tumors.